Literature DB >> 18940613

A potent peptidomimetic inhibitor of botulinum neurotoxin serotype A has a very different conformation than SNAP-25 substrate.

Jorge E Zuniga1, James J Schmidt, Timothy Fenn, James C Burnett, Demet Araç, Rick Gussio, Robert G Stafford, Shirin S Badie, Sina Bavari, Axel T Brunger.   

Abstract

Botulinum neurotoxin serotype A is the most lethal of all known toxins. Here, we report the crystal structure, along with SAR data, of the zinc metalloprotease domain of BoNT/A bound to a potent peptidomimetic inhibitor (K(i)=41 nM) that resembles the local sequence of the SNAP-25 substrate. Surprisingly, the inhibitor adopts a helical conformation around the cleavage site, in contrast to the extended conformation of the native substrate. The backbone of the inhibitor's P1 residue displaces the putative catalytic water molecule and concomitantly interacts with the "proton shuttle" E224. This mechanism of inhibition is aided by residue contacts in the conserved S1' pocket of the substrate binding cleft and by the induction of new hydrophobic pockets, which are not present in the apo form, especially for the P2' residue of the inhibitor. Our inhibitor is specific for BoNT/A as it does not inhibit other BoNT serotypes or thermolysin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18940613      PMCID: PMC2716802          DOI: 10.1016/j.str.2008.07.011

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  26 in total

1.  PHENIX: building new software for automated crystallographic structure determination.

Authors:  Paul D Adams; Ralf W Grosse-Kunstleve; Li Wei Hung; Thomas R Ioerger; Airlie J McCoy; Nigel W Moriarty; Randy J Read; James C Sacchettini; Nicholas K Sauter; Thomas C Terwilliger
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2002-10-21

2.  Coot: model-building tools for molecular graphics.

Authors:  Paul Emsley; Kevin Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-11-26

Review 3.  Recent developments in the design of specific Matrix Metalloproteinase inhibitors aided by structural and computational studies.

Authors:  B Govinda Rao
Journal:  Curr Pharm Des       Date:  2005       Impact factor: 3.116

4.  Substrate recognition strategy for botulinum neurotoxin serotype A.

Authors:  Mark A Breidenbach; Axel T Brunger
Journal:  Nature       Date:  2004-12-12       Impact factor: 49.962

5.  Arg(362) and Tyr(365) of the botulinum neurotoxin type a light chain are involved in transition state stabilization.

Authors:  Thomas Binz; Steffen Bade; Andreas Rummel; Astrid Kollewe; Jürgen Alves
Journal:  Biochemistry       Date:  2002-02-12       Impact factor: 3.162

6.  Probing the mechanistic role of glutamate residue in the zinc-binding motif of type A botulinum neurotoxin light chain.

Authors:  L Li; T Binz; H Niemann; B R Singh
Journal:  Biochemistry       Date:  2000-03-07       Impact factor: 3.162

Review 7.  Botulin toxin: a weapon in terrorism.

Authors:  Deborah Josko
Journal:  Clin Lab Sci       Date:  2004

8.  Structural analysis of botulinum neurotoxin type E catalytic domain and its mutant Glu212-->Gln reveals the pivotal role of the Glu212 carboxylate in the catalytic pathway.

Authors:  Rakhi Agarwal; Subramaniam Eswaramoorthy; Desigan Kumaran; Thomas Binz; Subramanyam Swaminathan
Journal:  Biochemistry       Date:  2004-06-01       Impact factor: 3.162

9.  Structure and enzymatic activity of botulinum neurotoxins.

Authors:  Subramanyam Swaminathan; Subramanian Eswaramoorthy; Desigan Kumaran
Journal:  Mov Disord       Date:  2004-03       Impact factor: 10.338

10.  Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin.

Authors:  G Schiavo; F Benfenati; B Poulain; O Rossetto; P Polverino de Laureto; B R DasGupta; C Montecucco
Journal:  Nature       Date:  1992-10-29       Impact factor: 49.962

View more
  27 in total

1.  Metal Ions Effectively Ablate the Action of Botulinum Neurotoxin A.

Authors:  Paul T Bremer; Sabine Pellett; James P Carolan; William H Tepp; Lisa M Eubanks; Karen N Allen; Eric A Johnson; Kim D Janda
Journal:  J Am Chem Soc       Date:  2017-05-19       Impact factor: 15.419

2.  NUPR1 maintains autolysosomal efflux by activating SNAP25 transcription in cancer cells.

Authors:  Yanchao Mu; Xiaojie Yan; Ding Li; Dan Zhao; Lingling Wang; Xiaoyang Wang; Dan Gao; Jie Yang; Hua Zhang; Yanzhe Li; Yanan Sun; Yiliang Wei; Zhenfa Zhang; Xinzhong Chang; Zhi Yao; Shanshan Tian; Kai Zhang; Lance S Terada; Zhenyi Ma; Zhe Liu
Journal:  Autophagy       Date:  2017-12-31       Impact factor: 16.016

3.  Structural and biochemical characterization of the protease domain of the mosaic botulinum neurotoxin type HA.

Authors:  Kwok-Ho Lam; Stefan Sikorra; Jasmin Weisemann; Hannah Maatsch; Kay Perry; Andreas Rummel; Thomas Binz; Rongsheng Jin
Journal:  Pathog Dis       Date:  2018-06-01       Impact factor: 3.166

4.  Epitope targeting of tertiary protein structure enables target-guided synthesis of a potent in-cell inhibitor of botulinum neurotoxin.

Authors:  Blake Farrow; Michelle Wong; Jacquie Malette; Bert Lai; Kaycie M Deyle; Samir Das; Arundhati Nag; Heather D Agnew; James R Heath
Journal:  Angew Chem Int Ed Engl       Date:  2015-04-29       Impact factor: 15.336

5.  The identification and biochemical characterization of drug-like compounds that inhibit botulinum neurotoxin serotype A endopeptidase activity.

Authors:  Shuowei Cai; Paul Lindo; Jong-Beak Park; Kruti Vasa; Bal Ram Singh
Journal:  Toxicon       Date:  2009-12-07       Impact factor: 3.033

6.  Newly Designed Quinolinol Inhibitors Mitigate the Effects of Botulinum Neurotoxin A in Enzymatic, Cell-Based, and ex Vivo Assays.

Authors:  Paul T Bremer; Michael Adler; Cecilia H Phung; Ajay K Singh; Kim D Janda
Journal:  J Med Chem       Date:  2017-01-03       Impact factor: 7.446

7.  Iterative structure-based peptide-like inhibitor design against the botulinum neurotoxin serotype A.

Authors:  Jorge E Zuniga; Jared T Hammill; Omri Drory; Jonathan E Nuss; James C Burnett; Rick Gussio; Peter Wipf; Sina Bavari; Axel T Brunger
Journal:  PLoS One       Date:  2010-06-30       Impact factor: 3.240

8.  Paclitaxel is an inhibitor and its boron dipyrromethene derivative is a fluorescent recognition agent for botulinum neurotoxin subtype A.

Authors:  Saedeh Dadgar; Zack Ramjan; Wely B Floriano
Journal:  J Med Chem       Date:  2013-03-29       Impact factor: 7.446

9.  Synthesis/biological evaluation of hydroxamic acids and their prodrugs as inhibitors for Botulinum neurotoxin A light chain.

Authors:  Hajime Seki; Sabine Pellett; Peter Silhár; G Neil Stowe; Beatriz Blanco; Matthew A Lardy; Eric A Johnson; Kim D Janda
Journal:  Bioorg Med Chem       Date:  2013-12-08       Impact factor: 3.641

10.  Potent new small-molecule inhibitor of botulinum neurotoxin serotype A endopeptidase developed by synthesis-based computer-aided molecular design.

Authors:  Yuan-Ping Pang; Anuradha Vummenthala; Rajesh K Mishra; Jewn Giew Park; Shaohua Wang; Jon Davis; Charles B Millard; James J Schmidt
Journal:  PLoS One       Date:  2009-11-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.